Business
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLCIvonescimab Is the First Drug to Achieve Clinically
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLCIvonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLCHONG KONG, Aug. 11, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) (\"Akeso,\") today announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (\"WCLC24\"), taking place in San Diego, USA from September 7-10, 2024. Among these is a late-breaking Presidential Symposium presentation featuring results from the HARMONi-2/AK112-303 study, which evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS ≥1%).\n\nThe late-breaking result of HARMONi-2/AK112-303 will be presented by Professor Zhou Caicun, the principal investigator of HARMONi-2 and director in the Department of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University.\nPresentations during WCLC 2024\nAbstract Title\nPresentation Details \nPhase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2\nSession: PL02 Presidential Symposium 1 (LIVESTREAMED)\nForm: Plenary oral\nPresenter: Caicun Zhou, MD. Ph.D, China Shanghai Pulmonary Hospital\nAbstract release time: embargoed until the presentation day \nA Phase 2 Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer\nSession: Perioperative Strategies 1—Early-Stage Non-Small Cell Lung Cancer\nSunday, September 8, 2024, 11:17 AM-11:27 AM\nForm: Oral\nPresenter: Xiaoliang Zhao, MD, China Tianjin Medical University Cancer Institute & Hospital\nAbstract release time: August 14, 2024\nAkeso will also participate as an exhibitor, actively engaging with professionals from diverse fields.\nMilestones of ivonescimab:\nMay 2024:Ivonescimab was granted marketing approval for the treatment of epidermal growth factor receptor (\"EGFR\") mutated locally advanced or metastatic non-squamous non-small cell lung cancer (\"nsq-NSCLC\"), making it the world's fir...